Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Sutro Biopharma

Biotech & Life Sciences · South San Francisco, United States · Founded 2003 · IPO 2018 Thoroughbred

Develops protein therapeutics by using OCFS protein synthesis technology

Valuation
$481M
Market cap · May/2026
Revenue
$102M
Latest reported FY

Investors

12 investors on Sutro Biopharma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage
International Biotechnology Trust
Series A 1 investor entered at this stage
SV Health Investors
Series B+ 10 investors entered at this stage
Tekla Capital Management
Samsara BioCapital
Skyline Ventures
Citadel
Alta Partners
Merck & Co.
Lilly Ventures
Celgene
Amgen Ventures
Vida Ventures

Global footprint

Where Sutro Biopharma has talent and traffic

AI talent share
0.9% of workforce is AI talent
(2 of 216 staff)
Core AI10.46%
Other AI10.46%
Non-AI workforce21499.07%
Workforce by country
2 countries with
team presence
🇺🇸 United States99.5%
🇩🇪 Germany0.5%
2 countries shown
Web traffic by country
16K monthly visits
across markets
🇺🇸 United States49.4%
🇨🇱 Chile11.3%
🇯🇵 Japan11.3%
🇬🇧 United Kingdom9.4%
🇮🇳 India6.9%
Top 5 markets shown

Market sentiment

What the market is saying about Sutro Biopharma

An AI-synthesized read of the highest-engagement posts about Sutro Biopharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Sutro Biopharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.